A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT
T cell immunoglobulin and ITIM domain (TIGIT) is a novel immune checkpoint that has been considered as a target in cancer immunotherapy. Current available bioassays for measuring the biological activity of therapeutic antibodies targeting TIGIT are restricted to mechanistic investigations because do...
Main Authors: | Zhihao Fu, Hongchuan Liu, Lan Wang, Chuanfei Yu, Yalan Yang, Meiqing Feng, Junzhi Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383521003531 |
Similar Items
-
Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity
by: Alyson J. Smith, et al.
Published: (2023-11-01) -
TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
by: Chenran Yue, et al.
Published: (2022-06-01) -
Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
by: Yu-Hang Duan, et al.
Published: (2022-09-01) -
Studying TIGIT activity against tumors through the generation of knockout mice
by: Ahmed Rishiq, et al.
Published: (2023-12-01) -
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
by: Hauke Stamm, et al.
Published: (2019-12-01)